Home Business NewsBusiness Fever-Tree upbeat about post-pandemic recovery as Brits drink at home

Fever-Tree upbeat about post-pandemic recovery as Brits drink at home

by LLB Editor
18th Mar 21 9:49 am

Fever-Tree today said it expects revenues to rebound this year past pre-pandemic levels, thanks to increased at-home drinking as well as the gradual easing of lockdown restrictions..

Tim Warrillow, Co-Founder and CEO of Fever-Tree, commented on Fever-Tree’s performance throughout the pandemic: “Our performance in the Off-Trade was especially strong, exceeding our expectations across all our regions. Numerous periods of lockdown during the year encouraged increased consumer interest in premium spirits and stimulated excitement about mixing drinks at home, attracting more households and new consumers to the Fever-Tree brand than ever before. Consequently, we have increased our penetration in the UK, driven value share gains in the US, and Europe, and gained real traction in Canada and Australia.”

“Despite the restrictions and closures that impacted the On-Trade for a large proportion of the year we didn’t furlough any of our team enabling us to support our customers across the On-Trade and Off-Trade, strengthening our relationships and securing new contracts.”

“Our resilient performance can also be attributed to the proactive and rapid actions taken by the business to respond to the evolving consumption and purchasing habits that emerged during the pandemic. Crucially, we did this while remaining focused on the longer-term opportunity.

“We expanded our team across all our regions, as well as acquiring our sales agent in Germany, and began local production in the US for the first time. We also launched new products with our Premium Soda range in the UK targeting the significant vodka category and Pink Grapefruit in the US targeting the fast-growing tequila category. Both launches were very encouraging, delivering an excellent rate of sale growth as well as attracting new consumers to the brand.”

 

Leave a Comment

You may also like

CLOSE AD

Sign up to our daily news alerts

[ms-form id=1]